Quick Answer
Artiva Biotherapeutics, Inc. reported Stockholders Equity of $109.97 million for the year ending 2025.
- Artiva Biotherapeutics, Inc. showed a decrease of -41.1% in Stockholders Equity from 2024 to 2025.
- This data is from Artiva Biotherapeutics, Inc.'s annual report (Form 10-K), filed with the SEC on March 10, 2026.
- XBRL data for this metric is available from 2022 to 2025 (4 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q1 2023: -$155.57 million | Q2 2023: -$164.26 million | Q3 2023: -$151.45 million | Q1 2024: -$174.67 million | Q2 2024: -$191.10 million | Q3 2024: $201.00 million | Q1 2025: $168.78 million | Q2 2025: $149.04 million | Q3 2025: $129.22 million.
- Over the full 4 years of available data (2022 to 2025), Artiva Biotherapeutics, Inc.'s Stockholders Equity has grown by 178.2%.
- Historical annual values: Fiscal year 2025: $109.97 million | Fiscal year 2024: $186.64 million | Fiscal year 2023: -$162.02 million | Fiscal year 2022: -$140.70 million.
- Data sourced from SEC EDGAR public filings as of August 5, 2026.
Last verified: